Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) CEO Massimo Calafiore acquired 10,000 shares of the company's stock in a transaction that occurred on Friday, May 9th. The shares were bought at an average cost of $12.54 per share, for a total transaction of $125,400.00. Following the transaction, the chief executive officer now owns 234,603 shares of the company's stock, valued at $2,941,921.62. This represents a 4.45% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Orthofix Medical Stock Performance
Shares of OFIX stock traded up $0.32 during midday trading on Monday, hitting $12.43. The company had a trading volume of 473,397 shares, compared to its average volume of 260,367. The company's 50 day simple moving average is $14.77 and its 200 day simple moving average is $16.90. Orthofix Medical Inc. has a 52-week low of $10.50 and a 52-week high of $20.73. The stock has a market cap of $485.04 million, a price-to-earnings ratio of -3.97 and a beta of 0.87. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on OFIX shares. Roth Mkm reissued a "buy" rating and issued a $22.00 price target on shares of Orthofix Medical in a report on Wednesday, February 26th. Canaccord Genuity Group reiterated a "buy" rating and set a $24.00 price target on shares of Orthofix Medical in a research report on Wednesday, February 26th. Finally, StockNews.com downgraded Orthofix Medical from a "buy" rating to a "hold" rating in a research note on Wednesday, May 7th.
Get Our Latest Research Report on OFIX
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the stock. Nuveen LLC purchased a new position in Orthofix Medical in the first quarter valued at about $1,445,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Orthofix Medical by 27.3% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 70,622 shares of the medical device company's stock worth $1,152,000 after acquiring an additional 15,150 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Orthofix Medical by 2.6% in the first quarter. Vanguard Group Inc. now owns 2,181,313 shares of the medical device company's stock worth $35,577,000 after acquiring an additional 54,528 shares during the last quarter. US Bancorp DE grew its position in shares of Orthofix Medical by 684.6% in the first quarter. US Bancorp DE now owns 5,673 shares of the medical device company's stock valued at $93,000 after purchasing an additional 4,950 shares during the period. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new stake in shares of Orthofix Medical in the first quarter valued at $164,000. 89.76% of the stock is currently owned by hedge funds and other institutional investors.
About Orthofix Medical
(
Get Free Report)
Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Orthofix Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orthofix Medical wasn't on the list.
While Orthofix Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
